Crucell 2008
Combating Infectious Diseases
Annual Report and Form 20–F

• What Corporate Social Responsibility means to us
• What we do
• A CSR dilemma
• Crucell on its mission to combat infectious diseases
• Who we work with
• An example: Warm response to cold chain training
• How we do business
• A partnership with customers illustrated
• Crucell's PER.C6^® technology
• How we see our responsibility
• Crucell works in an environment that requires highly skilled employees
• Innovative safety approach
• Beyond legislation for safety
• Environmental impact
• An example: Combining vaccines for a diversity of benefits
• Energy & water consumption
• Economic aspects of our business

A partnership with customers illustrated

Crucell’s work is supported by grants from both governmental and non-governmental organizations. Furthermore, Crucell works alongside other parties in order to reach common healthcare goals. One example of this type of cooperation is the GAVI Alliance, a global public-private partnership that brings together the talents of different constituencies and individuals to help the poorest parts of the world develop their own sustainable immunization programs. Within the alliance, Crucell invests time by working closely with other vaccine-producing companies, national governments, research and technical health institutes, supranational organizations (including the WHO, Unicef and The World Bank), the Gates Foundation and civil society organizations, in order to accelerate the introduction of new and underused vaccines.

This is considered crucial for meeting one of the United Nations (UN) Millennium Development Goals of reducing the mortality rate among children under five by two-third before 2015.

In September 2000 the UN set out concrete plans for action to meet the needs of the world’s poorest, which resulted in eight Millennium Development Goals, to be achieved by 2015. More information about the Millennium Development Goals can be found on the UN website www.un.org/millenniumgoals.

Crucell is a leading supplier of innovative vaccines to countries supported by the GAVI Alliance, and currently represents the industrialized countries’ vaccine industry on the Program and Policy Committee of the GAVI Alliance. This committee serves as the principal advisory body to the GAVI Board regarding program and policy development.